In inflammatory bowel disease, the upregulation of NKG2D ligands may be linked to NKG2D-mediated inflammatory and cytotoxic responses, providing a theoretical basis for potential therapeutic strategies targeting the NKG2D pathway, which could be beneficial in treating intestinal inflammation. This evidence concerns the gene KLRK1 and inflammatory bowel disease.